title: Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis.
abstract: The efficacy of intranasal fluticasone propionate 200 micrograms once daily or 100 micrograms twice daily in treating perennial allergic rhinitis was evaluated in a randomized, double-blind, placebo-controlled study of 24 weeks' duration in 365 patients. Clinician-rated and patient-rated total nasal symptom severity scores were improved within 1 week of treatment with either regimen of fluticasone propionate and improvement was maintained over the 24-week treatment period. Clinician-rated overall evaluation indicated a significantly better response in the two fluticasone propionate groups compared with the placebo group. All efficacy evaluations indicated no difference in response between the fluticasone propionate 200 micrograms once-daily and 100 micrograms twice-daily groups. Patients in both fluticasone propionate groups had significantly less nasal obstruction upon awakening than the placebo group at all assessment periods. Fewer patients in either fluticasone propionate group used antihistamine rescue medication compared with the placebo group. The percentage of patients with nasal eosinophils and basophils at the end of the 24-week treatment period was significantly lower in both fluticasone propionate groups compared with the placebo group. Safety evaluations indicated that intranasal fluticasone propionate was as safe as placebo when given as 200 micrograms once daily or 100 micrograms twice daily. The incidence of drug-related adverse events was similar among the fluticasone propionate and placebo groups except for the incidence of epistaxis and blood in nasal mucus which was somewhat higher in the fluticasone propionate twice-daily group. There was no changes in the opthalmic examinations to suggest corticosteriod-induced posterior subcapsular cataract formation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Research for Health, Inc, Houston, Texas.
authors.forename: C H
authors.initials: CH
authors.lastname: Banov
authors.forename: T R
authors.initials: TR
authors.lastname: Woehler
authors.forename: C F
authors.initials: CF
authors.lastname: LaForce
authors.forename: D S
authors.initials: DS
authors.lastname: Pearlman
authors.forename: M N
authors.initials: MN
authors.lastname: Blumenthal
authors.forename: W F
authors.initials: WF
authors.lastname: Morgan
authors.forename: H
authors.initials: H
authors.lastname: Frazer
authors.forename: D L
authors.initials: DL
authors.lastname: Southern
authors.forename: B
authors.initials: B
authors.lastname: Gold
authors.forename: E
authors.initials: E
authors.lastname: Field
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000188:drug therapy*; D012720:Severity of Illness Index; D013997:Time Factors
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone; D006854:Hydrocortisone